• Ultragenyx Pharmaceutical and Baylor Research Institute settled DOJOLVI patent litigation with Navinta on October 19, 2026.
• Navinta will receive a non-exclusive, royalty-free license to market generic DOJOLVI beginning January 1, 2033, subject to customary conditions and exceptions.
• The launch date would move to July 1, 2033, if DOJOLVI receives pediatric exclusivity.
• The litigation stemmed from Navinta's application for FDA approval of a generic version of DOJOLVI oral liquid.
• Similar DOJOLVI patent litigation against other generic applicants remains pending in the U.S. District Court for the District of New Jersey.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424739), on October 19, 2026, and is solely responsible for the information contained therein.